“PEGASEMP™ allows inhibition of tumor growth and prevents metastization of mesothelioma, with low incidence of side effects. PEGASEMP™ is the lead product of TREAT U that has just received the Orphan Drug designation (ODD) in the treatment of malignant mesothelioma … Continue reading →

Portugal Ventures challenged Vera Moura, our CEO, to describe the journey of a startup in Life Sciences sector. From “the commitment of a team”, “the growing pains” up to “finding a lead investor”, she is an example for others to … Continue reading →

TREAT U was one of six finalists for the Everis Awards, the awards for entrepreneurship, innovation and talent, with the PEGASEMP project. This award, promoted by the Everis Foundation (Spain) was created to encourage entrepreneurship in society and promote innovation … Continue reading →

JN Moreira presented a poster in the AACR Annual Meeting 2017, with the findings of the project ODD4PEGASEMP, co-funded by the European Union through the Centro2020 Program, Portugal 2020 and FEDER fund (reference 17646). Targeting nucleolin with doxorubicin-containing nanoparticle induces … Continue reading →